Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Role of adipose-derived stem cell exosomes in paclitaxel-induced acute ovarian injury: An experimental approach.

Yalcın B., Kalkan TK., Gonen ZB., Koseoglu E., Onder GO., Gokdemir NS.

Animal Study on Hair & Scalp, published in Reprod Toxicol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Reprod Toxicol (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40835101
DOI
10.1016/j.reprotox.2025.109033
Citations
1

Abstract (original English)

Paclitaxel (PTL) is commonly used in cancer therapy at varying doses and durations, often in combination with other chemotherapeutic agents. However, achieving therapeutic efficacy typically requires high doses, which are associated with considerable toxicity. Adipose-derived stem cells have shown therapeutic potential, particularly through the release of extracellular vesicles known as exosomes. This study investigated the potential protective effects of exosomes derived from adipose-derived mesenchymal stem cells (AMSC-Exos) in a rat model of PTL-induced acute ovarian injury. Twenty-eight rats were assigned to groups: control, PTL (7.5 mg/kg), AMSC-Exos (1 ×10 6 exosomes), and PTL+AMSC-Exos (7.5 mg/kg PTL + 1 × 10 6 exosomes). Three days after the administration, ovarian tissues were harvested for histological and biochemical analysis. Hematoxylin and eosin (H&E) and Masson's Trichrome (MT) staining revealed significant histopathological deterioration in the cortex and medulla of ovarian tissue in the PTL group compared to the PTL+AMSC-Exos group. Exosome treatment following PTL administration resulted in upregulation of VEGF and downregulation of HIF-1α, NF K B-p65, and IL-1β immunostaining intensities. Additionally, AMH immunostaining intensity was increased in primary, preantral, and secondary follicles. Levels of TNF-α, IL-1β, and IL-6 were significantly lower in the exos

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsFemaleExosomesPaclitaxelMesenchymal Stem CellsOvaryRats, Sprague-DawleyAdipose TissueAntineoplastic Agents, PhytogenicRats

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research